Portage Biotech 6-K Links Press Release to Key Filings
Ticker: ATON · Form: 6-K · Filed: Jan 4, 2024 · CIK: 1095435
| Field | Detail |
|---|---|
| Company | Portage Biotech INC. (ATON) |
| Form Type | 6-K |
| Filed Date | Jan 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, incorporation-by-reference, press-release, foreign-private-issuer
TL;DR
**Portage Biotech just linked a new press release to its public offering and employee stock plan filings.**
AI Summary
Portage Biotech Inc., a British Virgin Islands-based pharmaceutical company, filed a 6-K on January 4, 2024, indicating it is a foreign private issuer. This filing primarily serves to incorporate by reference a press release (Exhibit 99.1) into its existing Form F-3 (File No. 333-253468) and Form S-8 (File No. 333-275842) registration statements. This matters to investors because it ensures that important, recent information from the press release is officially linked to the company's public offering and employee benefit plan registration statements, providing transparency and legal compliance.
Why It Matters
This filing ensures that a recent press release, likely containing material information, is legally incorporated into Portage Biotech's active registration statements, making it officially part of the public record for investors.
Risk Assessment
Risk Level: low — This 6-K filing is a routine administrative update, primarily incorporating a press release by reference, and does not inherently introduce new risks.
Analyst Insight
Investors should review the referenced press release (Exhibit 99.1) to understand the specific information being incorporated, as it likely contains material updates relevant to the company's public offerings and employee plans.
Key Players & Entities
- Portage Biotech Inc. (company) — the registrant and foreign private issuer
- British Virgin Islands (company) — jurisdiction of incorporation for Portage Biotech Inc.
- January 2024 (date) — month of report for the 6-K filing
- Form 20-F (document) — annual report form filed by Portage Biotech Inc.
- Form F-3 (document) — registration statement for public offerings (File No. 333-253468)
- Form S-8 (document) — registration statement for employee benefit plans (File No. 333-275842)
- Exhibit 99.1 (document) — the press release being incorporated by reference
- Ian Walters (person) — Company Contact Person for Portage Development Services Inc.
- 416-737-7600 (dollar_amount) — Portage Biotech Inc.'s business phone number
- 203.221.7378 (dollar_amount) — Ian Walters' phone number
FAQ
What is the primary purpose of this 6-K filing by Portage Biotech Inc.?
The primary purpose of this 6-K filing is to incorporate by reference an exhibit, specifically a press release (Exhibit 99.1), into Portage Biotech Inc.'s existing registration statements on Form F-3 (File No. 333-253468) and Form S-8 (File No. 333-275842).
What type of company is Portage Biotech Inc. and where is it incorporated?
Portage Biotech Inc. is a pharmaceutical preparations company (SIC 2834) and is incorporated in the British Virgin Islands (Jurisdiction D8).
Which specific registration statements are affected by this incorporation by reference?
This report on Form 6-K incorporates the exhibit into the registration statement on Form F-3 (File No. 333-253468) and Form S-8 (File No. 333-275842) of Portage Biotech Inc.
Who is the company contact person listed in the filing and what is their contact information?
The company contact person listed is Ian Walters, c/o Portage Development Services Inc., with a phone number of 203.221.7378 and an address at 61 Wilton Road, Westport, Connecticut 06880.
What is the Commission File Number for Portage Biotech Inc.?
The Commission File Number for Portage Biotech Inc. is 001-40086.
Filing Stats: 274 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2024-01-04 08:10:06
Filing Documents
- f6k_010324.htm (6-K) — 7KB
- exh_991.htm (EX-99.1) — 8KB
- 0001171843-24-000055.txt ( ) — 16KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Portage Biotech Inc. (Registrant) Date: January 4, 2024 /s/ Allan Shaw Allan Shaw Chief Financial Officer